CSTL stock forecast
Our latest prediction for Castle Biosciences, Inc.'s stock price was made on the Sept. 23, 2020 when the stock price was at 50.29$.
In the short term (2weeks), CSTL's stock price should underperform the market by -1.01%. During that period the price should oscillate between -8.20% and +7.52%.
In the medium term (3months), CSTL's stock price should underperform the market by -1.97%. During that period the price should oscillate between -27.71% and +19.89%.Get email alerts
Create a solid portfolio with CSTL
About Castle Biosciences, Inc.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
At the moment the company generates 63M USD in revenues.
On its last earning announcement, the company reported a profit of 0.10$ per share.
The book value per share is 4.82$
Three months stock forecastSept. 23, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|